reSee.it - Related Video Feed

We are facing a new disease involving white clots found in post-mortem bodies, made of fibrin, platelets, and amyloid protein. Embalmers reported 20% of corpses showing these clots in 2023, a significant increase from previous years. These clots are not seen in pathology textbooks and need urgent investigation. Therapeutic interventions should be suspended until the cause is determined. This new pathology is present in about 20% of corpses, indicating a concerning trend. More details will be provided in the next video.

Dr. Pretorius and a colleague discuss unusual clotting observed after COVID-19 vaccination, including embalmers reporting back pressure when introducing embalming fluid and the extraction of very long, congealed clots—six inches to several feet—as well as patients with long brachial clots. They note thousands of clotting reports in VAERS across all vaccine types, describing these clots as not normal. Some clots cause major emboli affecting circulation to the lungs, detected by scans and perfusion studies, while others are microclots with a branching pattern visible in imaging. A clinician also shared a photo of a clot with a complete branching pattern into medium and smaller vessels. Dr. Pretorius’ work is cited to explain the mechanism: spike protein can induce immediate clumping of proteins in platelet-poor plasma in the absence of platelets, a highly unusual clotting pathway not relying on the classical coagulation cascade. This is described as a proteinaceous, pseudo-amyloid–like clot. The spike protein is reported to circulate after vaccination, with studies in the Journal of Immunology showing spikes in circulation and exosomes up to four months after shots. Long-haul COVID data (Patterson’s study) reportedly shows S1 protein present in nonclassical monocytes in blood, suggesting persistence of spike protein, whether from infection or the vaccine, which can induce clotting pathways on its own. Dr. Pretorius discusses observations of upregulation of intercellular adhesion molecules (ICAMs) on leukocytes within clots, causing white blood cells to adhere in addition to fibrin, contributing to difficulty in dissolving these clots. Concerning treatment and detection, the speakers describe depletion of plasminogen, reducing the body’s ability to break down clots, and note that standard anticoagulants are less effective against these clots, which are described as amyloid-like and atypical. They emphasize that these are not the classical clotting pathways involving platelet activation and typical thrombin–fibrin cascades. They contrast this with expectations of standard clotting mechanisms and reference the unusual, non-classical pathway highlighted by Pretorius. The discussion also mentions the idea that spike protein in circulation can drive clotting without the usual platelet activation, and that some patients have continued to experience spike-related effects long after vaccination. They assert that vaccines were developed targeting the original Wuhan strain and may not cover Omicron; they suggest the shot’s risk-benefit balance is unfavorable given ongoing clotting, immune suppression, and cancer-inducing pathways, and they claim data indicate those who receive two or three shots may acquire Omicron at a higher rate than those unvaccinated. They conclude that the shot is expired for a virus that is no longer circulating in its original form and argue that vaccination induces dangerous pathologic processes with no protective benefit.

I have an internal Pfizer document from a source who reverse-engineered the BioNTech Pfizer SARS COVID-2 vaccine. This document reveals the precise chemical and biological processes used to create an mRNA that contains graphene oxide, a dangerous toxin. Each vaccine contains 15 billion nanoparticles or lipid carrier particles within the mRNA sequence. Once injected, the spike protein binds to blood cells, and graphene oxide begins building a structure, leading to blood clots and heart failure. Patent databases and recovered, deleted Wuhan databases prove that COVID-19 and its vaccines are bioweapons.

As a doctor, the speaker states they have never seen something so injurious to the human body, invading the brain, heart, and bone marrow. It allegedly stimulates antibodies to attack platelets and other cells, causing unprecedented blood clotting and blood vessel damage. The speaker cites data from the University of Pittsburgh suggesting it causes cancer. They question how a single protein can injure the brain, heart, bone marrow, and immune system, cause blood clotting, and potentially cause cancer, calling it a weapon. The speaker references three papers, including one by Farkas in Military Medicine and Tubei Yan in preprint, which reportedly conclude that it is a bioweapon according to strict military criteria.

In this video, the speaker discusses the presence of white fibrous clots in bodies. They conducted a survey last year to determine if this phenomenon was real. The survey revealed that around 70% of embalmers were seeing these clots, with most of them noticing them after the rollout of vaccines in 2021. Some embalmers reported seeing these clots in up to 50% or more of the corpses they worked with. The speaker is currently conducting another survey to gather more information on what embalmers are observing in 2023.

Tom Haviland, a retired major in the US Air Force and an experienced embalmer, discusses the presence of white fibrous clots found in the circulatory systems of deceased individuals. These clots, which have been observed in a high percentage of corpses over the past three years, are believed to be made of amyloid protein and fibrin. Embalmers have noticed an increase in the size and prevalence of these clots, as well as an increase in microclotting or "coffee ground" clots. The data collected from embalmers suggests that these clots may be linked to the spike protein produced by the COVID-19 vaccines.

The clots being formed, we've run mass spectrometry on these clots. They don't look like normal clots. They don't have the same composition. They don't have fibrin. They don't have thrombin, which are normal things you would see in a normal coagulation cascade. They have, instead, all the fibrinogen chains—alpha, beta, and gamma. They have them in a strange differential where it's not one-to-one-to-one; it's about 36 to 16 to 4 by ratios. They're aberrantly cross-linked by sulfide bonds. There's a ton of tin for some reason. I don't know why there's tin in there, but there's a ton of tin in there and a ton of phosphorus. And the spike protein is actually coated in GLIKNAK, which is a phosphate donor. So that might explain all the phosphorus if it's providing the energetics or in some way by cleaving or creating phosphate bonds. So I think that that's a big problem because that's a slow progression of coagulopathy that's, I think, narrowing the lumens of the vascular system, which is contributing to some of the organ failure that we're seeing, some of the neurological symptomatology that we're seeing, some of the fatigue, and things of that nature. And then finally, the spike protein is shown to produce—it’s shown to induce misfolding of proteins and actually

I've examined blood samples and have observed anomalies in everyone I've tested, even myself. I'm now seeing things I never saw in un*vaxxed individuals before. I'm noticing unusual formations, like chains potentially building, which typically occurs when the blood is breaking down. These formations seem more noticeable during decomposition. What's interesting is that while the body decomposes, these anomalies don't. They change and morph into something else. The red blood cells are visible, but when these formations mass together, that's when they evolve or morph. It could happen at any moment.

There are real blood clots in living patients, as confirmed by surgical colleagues who have found and removed them. These clots contain fibrin, reticulin, and amyloid, which are difficult for the body to break down. Autopsies were discouraged early on, so these clots were not initially discovered. Morticians have noticed unusual back pressure when preserving bodies, indicating the presence of clots. These clots consist of collected proteins and unusual protein combinations. Nattokinase, an enzyme derived from fermented soy, has been found to break down fibrin and dissolve clots. It is worth considering as a natural supplement. Enzymatic mechanisms can help break down clots before they become larger and more problematic.

The speaker discusses the formation of white fibrous clots induced by the spike protein in the blood. These clots can lead to various health issues like heart attacks and strokes. The speaker mentions Nattokinase, an enzyme derived from fermented soy, which can break down fibrin and dissolve clots. They highlight that regions like Northern Japan, where fermented soy is consumed, have lower rates of heart disease and strokes. The speaker suggests trying Nattokinase as an enzymatic mechanism to break down clots before they worsen.

In this video, Richard Hirschman, an embalmer, discusses the abnormal blood clotting issues he has observed in bodies since early 2021. He shares that these clots are different from typical blood clots, as they are white, fibrous, and rubbery in texture. Hirschman believes that these clots may be caused by aberrant proteins resulting from the COVID vaccines. He emphasizes the need for further research and understanding of these clots and their potential impact on health. Another guest, Jamie, a funeral service professional, supports Hirschman's observations and urges people to critically evaluate the situation. The video also includes a discussion on the suppression of information and the need for scientific investigation.

A data analyst and former Air Force Major conducted a survey among embalmers nationwide. 72% reported seeing white fibrous blood clots in corpses in 2023. The analyst, Tom Haviland, conducted the survey after hearing reports of these clots. He sent out surveys to over 3 dozen funeral associations and 1700 funeral homes worldwide. The survey found that 7 out of 10 embalmers observed the clots, with most seeing them after the vaccine rollout in 2021. A follow-up survey is currently underway to gather more data for 2023.

Here's a shorter version of the transcript: We're examining fluorescent micrographs of plasma from healthy individuals. We're looking at a PPP smear, a smear with added spike protein, and plasma exposed to spike protein. The goal is to see if adding spike protein creates larger microclots than in healthy blood. We'll be conducting an experiment to investigate this. A question was raised about whether blood type matters, specifically if O positive individuals have fewer reactions to COVID. While I'm not certain, it's something to consider.

Our study investigates the impact of the SARS-CoV-2 spike protein on blood hypercoagulation. We used microscopy and mass spectrometry to examine the spike protein's interaction with platelets and fibrinogen. Results using platelet-poor plasma showed the spike protein may disrupt blood flow. Mass spectrometry revealed structural changes in beta and gamma fibrinogen, complement, and prothrombin after adding spike protein S1. These changes, similar to those observed in COVID-19 patient blood clots, showed resistance to trypsinization. We propose that the spike protein's presence in the bloodstream contributes to hypercoagulation in COVID-19 patients, potentially causing impaired fibrinolysis and persistent microclots. This finding has significant clinical implications. Our goal was to determine the spike protein's effects, as its interaction with these blood components warrants further investigation.

There are real cases of blood clots in patients who have received the vaccine. These clots are thick and fibrous and can be seen in living patients. A tube of blood from a patient with cold-induced finger pain showed the same fibrils as the clots. The body has difficulty breaking down the material in the clots, including amyloid. Autopsies were discouraged early on, so these clots may not have been discovered. Morticians have noticed unusual back pressure when preserving bodies. The clots contain collected proteins and unusual combinations that are hard to dissolve. Nattokinase, an enzyme found in fermented soy, can break down fibrin and may be helpful in dissolving clots.

The spike protein, according to research in South Africa, induces fibrin from fibrinogen, forming the backbone of clotting in a way not previously seen. Unlike normal fibrin clots that are easily broken down, clots formed from COVID or the spike protein from the vaccine are difficult to break down, causing issues for many people. A cardiologist stated that in their decades of practice, they have never treated as many blood clots as in the last five years. These blood clots occur after the virus infection and the vaccine because the spike protein causes blood clots. Therefore, it is reckless to continue vaccinating people and loading the body with spike protein, causing more blood clots. According to a paper in Cell (July 2021), the nucleoprotein, not the spike protein, supplied broad and durable immunity for the prevention of infection. The speaker questions why the vaccine wasn't changed to target the nucleoprotein once this information came to light.

I recently conducted a survey of embalmers, and 73% of the 269 respondents reported finding white fibrous clots in corpses during 2023. These clots, which consist of fibrin, platelets, and amyloid-like material, are suspected to be a contributing factor in strokes and heart attacks. Embalmers are finding these clots are making it necessary to use multiple injection sites, lengthening the embalming process. While similar clots were observed in 2020, during the initial COVID outbreak, their prevalence exploded with the introduction of vaccines in 2021. The spike protein from the virus and vaccines may be responsible for the formation of these clots. Additionally, embalmers are reporting increases in microclotting and traditional grape jelly clots. One theory suggests "frame shifting," where ribosomes misread the modified RNA code from vaccines, creating aberrant proteins that form amyloid material. I can be contacted at thomashaveland@sbcglobal.net.

White fibrous clots found in the living and dead recipients of mRNA vaccines are being ignored, but research reveals their composition and cause. The spike protein mutates fibrin into jagged, misfolded, insoluble amyloid, similar to prionic infections. Microclots form and align into large white clots, initiated by spike protein fragments like spike 601. Prolene, a "kinker protein" added to the spike protein, causes misfolding, with proline being prevalent in the clots. A 2021 paper showed the SARS CoV-2 spike induces abnormal blood clots due to the fibrinogen beta chain. Plasma exposed to the spike protein is imbalanced, with the fibrinogen beta chain being dominant. These clots contain four times the normal amount of phosphorus, released from lipid nanoparticles. Similar clots in 1988 were caused by sulfur-based heparin, which was resolved by reducing sulfur content. A 2017 paper showed altered phosphorus levels cause cancer. Thomas Havilland, who shares this information, is being ignored by mainstream and alternative media. Undertakers are seeing massive white fibrous clots at record levels.

Okay, let's get started. I need to find the right tools to draw blood, so please be patient. I'll put the scope back on so we can watch. Here are some micrographs: healthy predlopod plasma, then the same plasma with spike protein added. We want to see if adding spike protein directly to healthy blood creates larger microclots than we see in the samples with the spike protein already present. We'll compare the images to see the effects.

Involvers are seeing very unusual blood clots that they had never seen before until the last four or five years. These clots look like a cast of a particular part of the vascular system, with a main trunk and tributaries running off. Sometimes they are gelatinous, sometimes dry and rubbery. Involvers say they look like calamari and stretch like a rubber band. They are hard to break and have to be pulled apart with tension. These clots are different than the grape jelly clots or chicken fat clots that involvers have typically seen in the past. Chicken fat clots are yellowish, smaller, and tear easily, unlike these large white clots.

The speaker has been sequencing clots and found real human DNA, showing a signature of neutrophil extracellular traps, a reaction occurring in sepsis when the immune system clots around foreign entities. This process takes free-circulating DNA into clotting structures, leaving a specific signature. Sequencing reveals patient genome sequences that might predispose them to clotting. While billions received shots, not everyone clotted, suggesting a subset has a bad reaction. Genetic predispositions in the clotting cascade may increase risk. Initial analysis of two clots shows high-impact variants in genes involved in fibrin formation and clotting. Kevin McCarran's work demonstrates some clots bind thiophlavin, a marker for amyloid, suggesting a potential amyloidosis issue. Pathology needs careful examination as it may underlie clotting problems. This information is being suppressed, but citations are provided for reference.

The speaker discusses the formation of clots induced by the spike protein in the blood. These clots can be white and fibrous, and they can vary in size. The speaker mentions that these clots can lead to heart attacks or strokes if they block the flow of oxygen in the body. They also mention an enzyme called Nattokinase, derived from fermented soy, which can break down fibrin and dissolve clots. The speaker suggests that using enzymatic mechanisms to break down clots early can prevent the accumulation of amyloid proteins and the worsening of clots.

Speaker 0 describes an ICP analysis (Inductively Coupled Plasma Mass Spectrometry) of white clots, initially encountered about three years ago from samples provided by Richard. Mike Adams presented the initial findings. The ICP analysis showed the highest element in the white clots was phosphorus, followed by sodium, tin, then sulfur and carbon. They also found that there were no normal blood marker elements present in the white clots. Two laboratories in Europe were used to replicate the results; both reported aberrantly high levels of phosphorus, tin, sulfur, sodium, and carbon. To investigate further, they performed High Performance Liquid Chromatography (HPLC) to identify protein components. The highest level of protein found was fibrinogen. The HPLC analysis determined the kinds of fibrinogen chains present, and it showed that in the white clots the beta chain far exceeded the alpha and gamma chains, with a beta-gamma-alpha ratio. They noted they were not biochemists or medically qualified, but conducted simple research to understand why fibrinogen content was so high. Fibrinogen forms fibrils, which aligns with John O’Learny’s description of white clots as calamari-like in texture, matching the expected texture from fibrin. An amino acid analysis by colleagues revealed high levels of proline, aspartic acid, lysine, and about 18 other amino acids, all with phosphorus affinity. They reiterate that the element with the highest confirmed concentration in the white clot is phosphorus. They state that aberrant phosphorylation pathways can cause a range of problems in the human body. They claim three separate pieces of analysis confirm their findings, allowing them to piece together the pathway to the formation of white clots. They connect this to injections that use a lipid nanoparticle carrier, specifically a phospholipid. Their analysis indicates that when the phospholipid releases the mRNA core of the lipid nanoparticle, it exposes a phosphorus head of the phospholipid. The phospholipid reacts within the bloodstream with naturally formed fibrinogen, nucleating the white clot formation. They claim over 200 peer-reviewed papers confirm the pathway described. They specify that the DSPC phospholipid encapsulating the lipid nanoparticle liberates 80 to 90% of raw phosphorus heads as it releases the mRNA core. Those phosphorus heads react with fibrinogen in the bloodstream, causing the sandy blood and coffee-ground appearance as the nucleation pathway to final white clot formation. They add that the spike protein binds to phosphorylated fibrinogen; the body generates methylcetiopridine-generated spike protein in the bloodstream, which coagulates with phosphorylated fibrinogen, feeding a monomeric reaction that continues to grow. These particles are free-flowing in the blood and find anchor points on damaged endothelial layers. When endothelial layers are damaged via inflammation and the cytokine storm induced by the spike protein, the natural phospholipid layer of the endothelium opens up and forms anchor points for these nuclei. From these anchor points, the clots begin to grow. They acknowledge the complexity but describe this as a simple encapsulation of the process.

In this video, the speaker discusses a documentary about embalmers finding strange white fibrous clots in corpses. They highlight a statement made by an embalmer at a conference, where all attendees claimed to have seen these clots after the rollout of safe injections. The speaker contacts the Ohio Embalmers Association and confirms that the vice president also sees these clots. This prompts the speaker to conduct a survey, which reveals that 66% of embalmers have witnessed the clots, with some seeing them in up to 50% of corpses. The clots can be as long as 2 feet and may cause strokes and heart attacks by blocking veins and arteries.